PFE vs TSLA: Which Is the Better Buy?

Side-by-side comparison of Pfizer Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-05.
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
VS
Tesla, Inc. · Consumer Cyclical
$387.51
-45.0% upside to fair value
Grade D
QuantHub Verdict
PFE has more upside to fair value (+28.6%). PFE trades at a lower forward P/E (19.3x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric PFE TSLA
Current Price $26.33 $387.51
Fair Value Estimate $33.85 $213.13
Upside to Fair Value +28.6% -45.0%
Market Cap $149.8B $1,454.1B
Forward P/E 19.3x 330.0x
EV / EBITDA 12.9x 122.9x
Price / Sales 2.4x 15.3x
Price / FCF 16.5x 233.8x
Revenue Growth YoY -1.2% -3.1%
Gross Margin 70.3% 18.0%
Operating Margin 24.7% 4.6%
Return on Equity 8.7% 4.8%
Dividend Yield 0% 0%
FCF Yield 6.06% 0.43%
Analyst Consensus Hold Hold
Investment Thesis
PFE — Pfizer Inc.
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
TSLA — Tesla, Inc.
Tesla, Inc. is a leading global manufacturer of electric vehicles, energy storage, and solar products, led by CEO Elon Musk since 2008. The company has a mixed business quality profile with a strong brand and innovation leadership but faces significant challenges including declining automotive revenue, which fell nearly 10% year-over-year in 2025, and a 3.1% revenue decline in the most recent qua…
Accumulation Zones
Metric PFE TSLA
Zone Low $25.39 $159.85
Zone High $28.77 $181.16
In Buy Zone? Yes No
← PFE Research    TSLA Research →    All Research